Results 191 to 200 of about 412,417 (244)

SIRPγ limits effector differentiation of human CD8 T cells in response to subthreshold TCR-signaling. [PDF]

Immunohorizons
Morse M, Rodriguez X, Delarosa E, Rodriguez S, Shanil J, Sinha S.   +5 more
europepmc   +1 more source

Artificial Host‐Guest Recognition Directs Glycometabolically Engineered Macrophages to Tumors

Advanced Science, EarlyView.
Glycoengineered supramolecular macrophages (GSAR‐M) are developed using glycometabolic labeling for bioorthogonal host‐guest tumor targeting. This engineering approach unexpectedly enhances macrophage migration, phagocytosis, and pseudopodia formation. Consequently, GSAR‐M demonstrate robust tumor‐targeting specificity, effectively arrest tumor growth,
Zhiqing Yang, Qian Cheng, Ziyi Wang, Jianwen Wei, Qun Guan, Huazhong Yu, Qingwen Zhang, Caixia Yin, Ruibing Wang   +8 more
wiley   +1 more source

CLEC2B-KLRB1 axis acts as an immune checkpoint, governing the exhaustion of CD8⁺ T cells and their resistance to immune checkpoint blockade. [PDF]

J Immunother Cancer
Cheng J, Lu J, Gao Z, Xiao Y, Chen P, Zhou M, Huang D, Zhao Z, Zhang X, Zhao Y, Li M, Gu J.   +11 more
europepmc   +1 more source

A Spatially Directed Microneedle Patch Enables Intratumoral Co‐Delivery of FOLFIRINOX, Surufatinib, and Anti‐PD‐1 for Chemo‐Immunotherapy of Pancreatic Ductal Adenocarcinoma

Advanced Science, EarlyView.
A double‐layered shell‐core microneedle patch is developed to co‐deliver FOLFIRINOX, surufatinib, and anti‐PD‐1 for localized chemo‐immunotherapy of PDAC. This strategy achieves sustained tumor suppression, reduces metastasis, and reprograms the TME by enhancing CD8+ T‐cell infiltration and inhibiting Tregs and M2 macrophages infiltration, while ...
Tingting Kong, Ximo Xu, Xiao Zhang, Chuntao Wu, Zhengjun Qiu, Beiyuan Hu, Zihao Qi, Qiang Tian, Yuqin Yang, Hanguang Dong, Fei Wu, Tuo Jin, Yan Zheng, Jiang Long   +13 more
wiley   +1 more source

CD8 regulatory T cell therapy in transplantation: a new path to clinical success? [PDF]

Transpl Int
Muller YD, Zuber J.
europepmc   +1 more source

Cobalt Single‐Atom Nanozyme for Enhanced Intestinal Radioprotection and Tumor Radiosensitization via Bidirectional ROS Modulation

Advanced Science, EarlyView.
Orally administered, pH‐responsive Co‐SAN exerts dual functions: in the alkaline intestinal milieu, it scavenges reactive oxygen species (ROS) and suppresses the PI3K/AKT pathway and NETs formation, thus providing radioprotection; whereas in the acidic tumor microenvironment, it generates ROS and alleviates hypoxia, thereby enhancing radiosensitization.
Shengqi Yin, Junjie Li, Yishu Zou, Yang Liu, Yilin Zheng, Lu Yu, Wanying Zheng, Yajun Zou, Zehui Zhang, Tao Li, Peiqun Yin, Jianlin Zhang, Yuen Wu, Yi Ding   +13 more
wiley   +1 more source

Repurposing licensed viral vaccines as anti-cancer therapeutics: Turning cold tumors hot. [PDF]

Hum Vaccin Immunother
de Bont DA, Reugebrink M, van Montfoort N, Kemp V.   +3 more
europepmc   +1 more source

A Novel IDO1/NE Dual Inhibitor, IMM‐H018 Prevents the Primary and Secondary Sepsis and Ameliorates the Kidney Injury Through Inhibiting the Cytokine Storm and Microthrombosis, and Reversing Immunosuppression

Advanced Science, EarlyView.
IMM‐H018, a dual IDO1/NE inhibitor, demonstrates potent therapeutic efficacy in sepsis by simultaneously targeting excessive inflammation and immune dysfunction. It prevents both primary and secondary sepsis through anti‐inflammatory, immune‐restoring, and renoprotective mechanisms, reducing organ damage, improving immune homeostasis, preserving kidney
Yi Zhou, Xiaodi Zhao, Xiaochen Pan, Zhiling Ma, Huaqing Cui, Hui Wen, Peng Wang, Xiufeng Liao, Kejie Qin, Yuchen Wang, Li Sheng, Sen Zhang   +11 more
wiley   +1 more source

Idecabtagene vicleucel and endogenous T-cell phenotypes linked to progression-free survival in relapsed multiple myeloma. [PDF]

Hemasphere
Paiva B, Manrique I, Thompson E, Campbell TB, Guerrero C, Martin N, Anderson LD, Berdeja JG, Lonial S, Raje NS, Lin Y, Moreau P, San-Miguel JF, Munshi NC, Kaiser S.   +14 more
europepmc   +1 more source

Dual Blockade of LILRB1 and LILRB2 Enhances Antiviral Immune Responses in SIV Infection

Advanced Science, EarlyView.
Dual LILRB1/B2 blockade with mac20G10 reshapes myeloid activation during acute SIV infection by targeting LILRB1 and LILRB2 on myeloid cells. This treatment enhances CD80 expression on selected myeloid subsets and increases plasma IFN‐λ, IL‐8, and IL‐1RA.
Florian Meurisse, Sixtine Coindre, Anne Wijkhuisen, Romain Marlin, Laure Fournier Le Ray, Juliette Pons, Melyssa Yaugel‐Novoa, Véronique Avettand‐Fenoel, Laurent Abi‐Rached, Anne‐Sophie Gallouet, Francis Relouzat, Mael Gourves, Asier Saez‐Cirion, Hisashi Arase, Gerard Zurawski, Sandra Zurawski, Nathalie Dereuddre‐Bosquet, Roger Le Grand, Stéphanie Simon, Olivier Lambotte, Benoit Favier   +20 more
wiley   +1 more source